Digistain: A Novel, Rapid, and Cost-effective Prognostic Marker for Guiding Adjuvant Therapy in ER+, HER2-Breast Cancer

被引:0
|
作者
Amrania, Hemmel [1 ]
机构
[1] Imperial Coll London, Harrow, Middx, England
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
1387998
引用
收藏
页码:S321 / S321
页数:1
相关论文
共 50 条
  • [31] Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2-breast cancer
    Elias, Anthony D.
    Staley, Alyse
    Fornier, Monica
    Vidal, Gregory A.
    Sams, Sharon
    Spoelstra, Nicole
    Kabos, Peter
    Diamond, Jennifer R.
    Shagisultanova, Elena
    Gallagher, Rosa I.
    Wulfkuhle, Julia
    Petricoin, Emanuel
    Zolman, Kathryn
    Biller, Stephanie
    Alami, Vida
    McSpadden, Tessa
    Borges, Virginia
    Crump, Lyndsey S.
    Gao, Dexiang
    Richer, Jennifer K.
    [J]. CANCER RESEARCH, 2023, 83 (08)
  • [32] Laboratory analyses of metastatic ER+/Her2-breast cancer treated with fulvestrant plus enzalutamide.
    Richer, Jennifer K.
    Spoelstra, Nicole S.
    Winchester, Alyse
    Wulfkuhle, Julia
    Sams, Sharon B.
    Vidal, Gregory
    Kabos, Peter
    Diamond, Jennifer
    Shagisultanova, Elena
    Afghahi, Anosheh
    Mayordomo, Jose
    McSpadden, Tessa
    Crawford, Gloria
    Borges, Virginia
    Gao, Dexiang
    Petricoin, Emanuel
    Elias, Anthony D.
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [33] Effect of adjuvant chemotherapy in patients with ER+/HER2-breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status
    Tanaka, Natsuko
    Hirano, Akira
    Hattori, Akinori
    Ogura, Kaoru
    Kamimura, Mari
    Inoue, Hiroaki
    Yukawa, Hiroko
    Sakaguchi, Shiho
    Matsuoka, Aya
    Kodera, Asaka
    Shimizu, Tadao
    [J]. BREAST CANCER, 2021, 28 (01) : 40 - 47
  • [34] Everolimus plus endocrine vs endocrine therapy in treatment advanced ER+, HER2-breast cancer patients: A meta-analysis
    Wang, Na
    Wang, Kai
    Liu, Ya-ting
    Song, Fei-xue
    [J]. CURRENT PROBLEMS IN CANCER, 2019, 43 (02) : 106 - 114
  • [35] Predicting sensitivity to CDK4/6 inhibition in ER+/HER2-breast cancer cell lines
    Bathurst, Lauren
    Liao, Linda
    Crozier, Cheryl
    Bayani, Jane
    Bartlett, John
    Spears, Melanie
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [36] Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2-breast cancer
    Moldoveanu, Dan
    Hoskin, Tanya L.
    Day, Courtney N.
    Schulze, Amy K.
    Goetz, Matthew P.
    Boughey, Judy C.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (03) : 419 - 428
  • [37] EndoPredict-based treatment decision can reduce chemotherapy usage in ER+, HER2-breast cancer
    Schlake, G.
    Kronenwett, R.
    Tiecke, F.
    Kastrup, K.
    Bleuel, N.
    Petry, C.
    Wilhelms, S.
    Toennies, P.
    Schlake, W.
    [J]. BREAST, 2015, 24 : S107 - S107
  • [38] Predictive model algorithms identifying early and advanced stage ER+/HER2-breast cancer in claims data
    Beachler, Daniel C.
    de Luise, Cynthia
    Yin, Ruihua
    Gangemi, Kelsey
    Cochetti, Philip T.
    Lanes, Stephan
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (02) : 171 - 178
  • [39] MRI Patterns in the evaluation of pathological response after Neoadjuvant Endocrine therapy in ER+/HER2-Breast Cancer and Implications on Surgical Planning
    Nakad, B.
    Milevsky, D.
    Simovici, P.
    Brodsky, A.
    [J]. BREAST, 2023, 68 : S57 - S58
  • [40] PAM50-based ROR indexes as a tool to individualize the use of neoadjuvant endocrine therapy in ER+/HER2-breast cancer
    Lopez Velazco, J. I.
    Manzano, S.
    Elorriaga, K.
    Lahuerta Martinez, A.
    Alvarez, L. A.
    Etxabe Azkue, I.
    Huarte Martinez, M.
    Buch, E.
    Gimenez Climent, J.
    Quiroga Garcia, V.
    Aragon, S.
    Pare, L.
    Prat, A.
    Alvarez Lopez, I.
    Munoz Caffarel, M.
    Urruticoechea, A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S168 - S169